Apixaban for Extended Treatment of Provoked VTE: New NEJM Study Challenges Treatment Paradigm
Emma P. with Clinical Research Professionals shared a post on LinkedIn:
“Apixaban for Extended Treatment of Provoked Venous Thromboembolism
A recent publication in The New England Journal of Medicine explores the benefits of continuing anticoagulation therapy with apixaban in patients who experienced venous thromboembolism (VTE) due to transient provoking factors like surgery, trauma, or immobility. Traditionally, these patients receive short-term anticoagulation, but this study challenges that paradigm.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
* Study Design:
Researchers conducted a randomized, double-blind trial comparing extended apixaban therapy to placebo in patients with provoked VTE who had completed initial anticoagulation. The goal: assess whether continued treatment could prevent recurrence without increasing bleeding risk.
* Key Findings:
• Apixaban reduced recurrent VTE by 82% compared to placebo.
• Major bleeding rates were low and comparable between groups.
• The benefit was consistent across subgroups, including those with persistent risk factors like obesity or cancer history.
* Clinical Implications:
This study suggests that extended apixaban therapy may be appropriate for select patients with provoked VTE, especially when enduring risk factors exist. It calls for a more individualized approach to anticoagulation duration—balancing recurrence risk with bleeding concerns.
* Why It Matters:
VTE remains a leading cause of preventable hospital death. This research could reshape guidelines and improve long-term outcomes for thousands of patients annually.
For clinicians, researchers, and policy-makers: this is a pivotal moment to re-evaluate how we define “provoked” VTE and tailor treatment accordingly.
Clinical and Research Focus
Broader Impact and Engagement.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch